Industry Presentations

New Data for A Treatment Option in Non-Metastatic CRPC


Presentations


Speakers

  • William J. Aronson, MD

    William J. Aronson, MD

    William J. Aronson, MD

    Professor

    Dr. Aronson obtained his undergraduate Degree from the University of Wisconsin, Madison, his Medical Degree from Washington University in St. Louis, and did his Urology training at UCLA. Dr. Aronson is a Professor in the UCLA Department of Urology. He is funded by The National Cancer Institute to research the role of low-fat diets, fish oil, and other nutritional components for prostate cancer prevention and treatment. Dr. Aronson conducts clinical trials for early and advanced stages of prostate cancer. He has over 200 publications in peer reviewed journals including The New England Journal of Medicine, The Journal of Clinical Oncology, Cancer Research, The Journal of the National Cancer Institute, and The Journal of Urology.
  • Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS

    Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.

    Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 175 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals.

    A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
  • Kenneth M. Kernen, MD

    Kenneth M. Kernen, MD

    Kenneth M. Kernen, MD

    Director of Clinical Research

    Kenneth M. Kernen, MD, is a partner in, and the director of clinical research for, the Michigan Institute of Urology in Troy. Dr Kernen received his medical degree from Wayne State University School of Medicine in Detroit, Michigan, completed his urologic residency at William Beaumont Hospital in Royal Oak, Michigan, and his urologic oncology fellowship at Baylor College of Medicine in Houston, Texas. He is the chief of urology at William Beaumont Hospital, Troy, where he is also the founding director of the Prostate and Urologic Cancer Multidisciplinary Clinic and clinical chair of the Robotic Surgical Committee. Additionally, he is co-director of the Urology Center for Excellence at Beaumont Health Systems.
  • Matthew Rettig, MD

    Matthew Rettig, MD

    Matthew Rettig, MD

    Professor of Medicine and Urology

    Matthew Rettig, M.D. is the Chief of Hematology-Oncology at the VA Medical Center in Greater Los Angeles and is a Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA. He serves as the Medical Director of the Prostate Cancer Program of the Institute of Urologic Oncology at UCLA. He is also the national Co-Director of the VA Precision Oncology Program Cancer of the Prostate (POPCaP), which aims to select treatments for advanced prostate cancer patients based on the genetic profile of their cancer. Dr. Rettig received his medical degree from Duke University and internal medicine residency at the University of Washington, before going on to a hematology-oncology fellowship at UCLA. Dr. Rettig’s focus is on management of genitourinary malignancies, with a clinical emphasis on advanced prostate cancer and research emphasis on identifying biochemical targets for therapeutic translation in castration-resistant prostate cancer.